预约演示

更新于：2026-03-16

Paclitaxel

紫杉醇

更新于：2026-03-16

概要

基本信息

药物类型

小分子化药

别名

EmPAC、LDE-paclitaxel、NanoPac

+ [75]

靶点

Tubulin

作用方式

抑制剂

作用机制

微管蛋白抑制剂

治疗领域

肿瘤感染消化系统疾病+ [12]

在研适应症

晚期胃癌转移性胰腺腺癌转移性乳腺癌+ [219]

非在研适应症

异戊酸血症急性淋巴细胞白血病食管腺癌+ [204]

原研机构

National Institutes of Health

在研机构

AstraZeneca AB

The University of Texas MD Anderson Cancer CenterClinigen KK

+ [56]

非在研机构

Eastern Cooperative Oncology Group

Inceptua SA

Radiation Therapy Oncology Group

+ [63]

权益机构

深圳市康哲药业有限公司

沈阳三生制药有限责任公司

Hanmi Pharmaceutical Co., Ltd.

+ [26]

最高研发阶段批准上市

首次获批日期

美国 (1992-12-29),

艾滋病相关性卡波西肉瘤乳腺癌卵巢癌

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)、孤儿药 (欧盟)、优先审评 (中国)

登录后查看时间轴

结构/序列

分子式C47H51NO14

InChIKeyRCINICONZNJXQF-MZXODVADSA-N

CAS号33069-62-4

关联

2,848

项与紫杉醇相关的临床试验

NCT07346196

/ Not yet recruiting临床2期IIT

A Randomized Phase II Trial of Induction Cemiplimab Plus Chemotherapy With or Without Fianlimab in Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck

The goal of this clinical trial is to learn if the combination of cemiplimab and fianlimab can improve outcomes compared to cemiplimab alone in adults with Human Papillomavirus Positive HPV-positive head and neck cancer.

开始日期2027-02-07

申办/合作机构

The University of Chicago

NCT07195734

/ Recruiting临床2期IIT

A Phase II Randomized Trial of Neoadjuvant Chemotherapy or Chemo-Immunotherapy in Patients With Recurrent/Persistent PD-L1 Enriched Squamous Cell Carcinoma of the Head and Neck Undergoing Salvage Surgery (NEOPOLIS)

This phase II trial tests the addition of chemotherapy, with carboplatin and paclitaxel, or chemo-immunotherapy, with carboplatin, paclitaxel and cemiplimab to standard salvage surgery followed by post operative radiation therapy and cisplatin for high risk patients, for the treatment of patients with PD-L1 positive head and neck squamous cell carcinoma that has come back and spread to nearby tissue or lymph nodes after a period of improvement (locally recurrent) or is persistent. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Salvage surgery is surgery that takes place to remove tumor tissue after a failure of other treatment. High risk patients also receive radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Adding chemotherapy or chemo-immunotherapy to standard salvage surgery may kill more tumor cells than salvage surgery alone in patients with PD-L1 positive locally recurrent or persistent head and neck squamous cell carcinoma.

开始日期2026-10-09

申办/合作机构

National Cancer Institute

NCT05411237

/ Not yet recruiting临床3期IIT

A Phase III, Randomized, Open-Label, Non-Inferiority Study of Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma in Resource-Limited Settings

This study is being done to determine if two different anti-cancer drugs, paclitaxel (PTX) and pegylated liposomal doxorubicin (PLD) have similar effects on treating Kaposi Sarcoma (KS) in people living with HIV (human immunodeficiency virus) in sub-Saharan Africa. Patients with HIV-related KS will receive either PTX or PLD once every 3 weeks for a total of six cycles.

开始日期2026-09-01

申办/合作机构

National Cancer Institute

100 项与紫杉醇相关的临床结果

登录后查看更多信息

100 项与紫杉醇相关的转化医学

登录后查看更多信息

100 项与紫杉醇相关的专利（医药）

登录后查看更多信息

49,215

项与紫杉醇相关的文献（医药）

2026-12-31·Future Science OA

Clinical efficacy of 2-week and 3-week albumin-bound paclitaxel therapy for advanced pancreatic cancer

Article

作者: Su, Zhimin ; Li, Zhiyong ; Shen, Feng ; Jiang, Jiana

OBJECTIVE:

We aim to compare the clinical efficacy and safety of albumin-bound paclitaxel (nab-PTX) (125 mg/m2, q2w) for two weeks and (125 mg/m2, d1, d8, q3w) for three weeks in the first-line treatment of advanced pancreatic cancer.

METHODS:

The medical records of patients with advanced pancreatic cancer who received nab-PTX for 2 weeks and 3 weeks, combined with gemcitabine, from July 2018 to January 2023, were retrospectively analyzed. The efficacy and adverse reactions of the two groups of patients were compared.

RESULT:

A total of 64 patients were included. The median progression-free survival (mPFS) of the 2-week group was 5.6 months, while the 3-week group was 7.8 months. The median overall survival (mOS) of the 2-week group was 14.0 months, while the 3-week group was 14.7 months. The multivariate analysis showed that a physical fitness status score of 0-1 was an independent factor with better OS, while metastatic sites ≥ 3 were related to poor OS. The incidence of leukopenia or neutropenia, neurotoxicity, fatigue, and poor appetite in the 2-week group was lower than that in the 3-week group.

CONCLUSION:

The clinical efficacy of nab-PTX in the 2-week and dose intensive 3 week did not show significant difference, but the 2-week treatment group had better tolerance and safety.

2026-12-31·ANNALS OF MEDICINE

Comparative effectiveness of percutaneous coronary intervention strategies for coronary small-vessel disease: a network meta-analysis of randomized trials

Review

作者: Du, Zhiyan ; Xu, Yixin ; Wang, ZhiLong ; Fan, Chao ; Jiang, Zhihui ; Wu, Tingting ; Zheng, Yingying ; Lv, Mingming ; Pan, Ying ; Adilijiang, Adilai. ; Bai, Bingxin ; Xie, Xiang ; Deng, Changjiang

BACKGROUND:

Coronary small-vessel disease (SVD) remains challenging for percutaneous coronary intervention (PCI) because small lumens magnify restenosis and ischemic risk. Multiple devices are available, yet their comparative performance is uncertain. This study evaluated and ranked PCI strategies for SVD.

METHODS:

A systematic review and network meta-analysis was conducted in accordance with PRISMA. PubMed, Embase, the Cochrane Central Register of Controlled Trials, Web of Science, and Google Scholar were searched from inception to 15 August 2025. Eligible studies were English-language randomized controlled trials enrolling adults with angiographic SVD defined as reference vessel diameter ≤3.0 mm, comparing PCI strategies, and reporting target lesion revascularization (TLR), binary restenosis (BR), or myocardial infarction (MI). A frequentist random-effects network meta-analysis generated odds ratios (ORs) with 95% confidence intervals (CIs) and treatment rankings using the surface under the cumulative ranking curve (SUCRA).

RESULTS:

Thirty-nine trials including 14,503 patients met the criteria. For TLR (37 studies; 11,980 patients), the highest SUCRA values were observed with sirolimus-eluting stents (SES 90.1%), zotarolimus-eluting stents (ZES 83.9%), and everolimus-eluting stents (EES 82.2%). For BR (32; 6,468), SES, ZES, and paclitaxel-coated balloons (DCB-PTX) ranked highest (95.0%, 80.0%, and 78.3%). For MI (37; 11,602), SES, DCB-PTX, and ZES ranked highest (79.0%, 78.7%, and 68.5%). Representative effects showed SES reduced TLR versus bare-metal stents (BMS) (OR, 0.25; 95% CI, 0.15-0.43) and MI versus BMS (OR, 0.41; 95% CI, 0.21-0.79). Conventional approaches such as BMS, plain old balloon angioplasty (POBA), and gold-plated balloon angioplasty (GPBA) ranked lowest across outcomes.

CONCLUSION:

SES provides the most consistent clinical benefit for coronary SVD. ZES, EES, and DCB-PTX are effective alternatives in selected settings, whereas BMS, POBA, and GPBA are less effective. These findings offer comparative evidence to guide device selection in SVD.

2026-12-31·OncoImmunology

A mixed inflammatory peripheral signature defines clinical outcomes in a phase II trial combining pembrolizumab with paclitaxel and carboplatin in melanoma

Article

作者: Cocolakis, Eftihia ; Cailhier, Jean-François ; Lapointe, Réjean ; Thébault, Paméla ; Shechtman, Yelena ; Lepage, Stéphanie ; Letendre, Caroline ; Le, Huy ; Dionne, Jeanne ; Bélanger, Karl ; Jamal, Rahima ; Lambert, Caroline ; Miller Jr, Wilson H.

Checkpoint blockade of PD-1 with pembrolizumab provides long-term survival to a significant proportion of patients with metastatic melanoma. Pembrolizumab has been successfully used in combination with chemotherapy in non-small-cell lung cancer to increase the response rate. This phase II trial combined pembrolizumab with carboplatin/paclitaxel (CP) to assess its safety and efficacy, and to identify correlates of responses. Thirty patients without prior immunotherapy for unresectable/metastatic melanoma were treated with pembrolizumab and CP. Peripheral blood was collected at baseline and after 2 cycles to characterize systemic immune activity by multiplex assays and flow cytometry. Seventy percent of patients received all 4 cycles of CP; 87% received pembrolizumab for 2 y or until progression. Grade 3 and higher adverse events (AEs) occurred in 50% of the patients. The overall response rate (ORR) and disease control rate (DCR) by irRC criteria were 43% and 53%, respectively. Median overall survival (OS) was 23.8 months. Objective response was associated with a lower frequency of naive CD8 T cells and low plasma CCL3 at baseline, along with a larger proportion of mature NK cells and of CD4 T cells expressing BTLA or LAIR-1. Survival rate was higher for patients with lower baseline of IL-6, IL-8, and CD4⁺CD39⁺ T cells. Following treatment, pro-inflammatory soluble factors increased in both responders and non-responders. Addition of CP to pembrolizumab in this study did not appear to result in a response or survival advantage and was less tolerable than immunotherapy alone. Correlative data point to peripheral signals to investigate further as potential biomarkers. Trial registration: clinicaltrials.gov, NCT02617849, registered on December 1st, 2015.

5,293

项与紫杉醇相关的新闻（医药）

14 小时之前

·ioncology

口服紫杉醇对乳腺癌疗效不逊静脉

点击上方蓝字关注我们紫杉醇问世60年以来，已被广泛用于各种癌症化疗，并被列入世界卫生组织基本药物标准清单。不过，紫杉醇口服生物利用度仅6.5%，过去主要通过静脉注射，用药不便，而且过敏反应和周围神经病变等不良反应较多。2007年，韩国科学技术研究院、高丽大学和大化制药首先研发出紫杉醇脂质自乳化溶液口服有效，并于2016年被韩国批准用于胃癌、2024年被中国批准用于胃癌、2025年进入中国医保目录（限一线含氟尿嘧啶类方案治疗期间或治疗后出现疾病进展的晚期胃癌患者）。那么，口服紫杉醇与静脉紫杉醇相比，对乳腺癌效果如何？ 2026年3月13日，欧洲肿瘤内科学会官方期刊《肿瘤学年鉴》在线发表中国医学科学院肿瘤医院徐兵河、辽宁省肿瘤医院孙涛、哈尔滨医科大学附属肿瘤医院张清媛、浙江省肿瘤医院王晓稼、天津市肿瘤医院佟仲生、中山大学肿瘤防治中心王树森、临沂市肿瘤医院王京芬、吉林大学第一医院李薇、复旦大学附属肿瘤医院胡夕春、韩国蔚山大学首尔峨山医院、延世大学世福兰斯医院、国家癌症中心、抱川中文医科大学盆唐医院、仁济大学海云台白医院、首尔大学医院、高丽大学九老医院、韩国天主教大学首尔圣玛丽医院、塞尔维亚贝尔格莱德大学医院、尼什大学医院的OPTIMAL研究报告，首次对口服紫杉醇制剂或静脉注射紫杉醇一线治疗晚期乳腺癌的有效性和安全性进行随机分组比较。 OPTIMAL (NCT03315364): Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy Official Title: A Multinational, Multicenter, Open-label, Phase II/III Clinical Trial to Evaluate the Efficacy and Safety of Liporaxel (Oral Paclitaxel) Compared to Taxol (IV Paclitaxel) as First-line Therapy in Patients With Recurrent or Metastatic HER2 Negative Breast Cancer 该国际多中心非盲随机对照三期临床研究于2018年1月至2023年12月从中国、韩国和塞尔维亚51家医院入组乳腺癌复发或转移后尚未化疗患者549例（远处转移542例，占98.7%；HER2阳性115例，占20.9%；中国患者290例，占52.8%）按1比1随机分为两组每28天第1、8和15天进行化疗，其中277例口服紫杉醇制剂每平方米体表面积200毫克，其余272例静脉注射紫杉醇每平方米体表面积80毫克，治疗持续至疾病进展或出现不可耐受的毒性反应。主要终点为研究者评定符合方案（完成至少前3周治疗和1次肿瘤复查）患者无进展生存，预设风险比非劣效界值为1.33。次要终点包括独立集中复核无进展生存、总生存、肿瘤缓解、生活质量和安全性。结果，截至2024年2月19日，中位随访将近40个月，其中519例患者，口服紫杉醇制剂组262例与静脉注射紫杉醇组257例相比：中位无进展生存：10.0个月比8.5个月进展或死亡风险：减少13.1%（风险比：0.869，95%置信区间：0.707～1.068）中位总生存：32.6个月比31.8个月总死亡风险：减少3.3%（风险比：0.967，95%置信区间：0.762～1.227）口服紫杉醇制剂组中性粒细胞减少、发热性中性粒细胞减少、恶心、腹泻和呕吐发生率较高，未发生治疗相关死亡；静脉注射紫杉醇组周围神经病变和过敏反应发生率较高，死亡1例（0.4%）。两组患者的生活质量评分相似。因此，该研究结果表明，对于乳腺癌复发或转移后尚未化疗患者，口服紫杉醇制剂与静脉注射紫杉醇相比，疗效并不逊色，安全性良好，可以作为有效且方便的替代治疗方案。 Ann Oncol. 2026 Mar 13. IF: 65.4 OPTIMAL: A Multinational Phase III Study of Oral Paclitaxel (DHP107) versus Intravenous Weekly Paclitaxel in HER2-Negative Recurrent or Metastatic Breast Cancer. Xu B, Jeong H, Sun T, Sohn J, Zhang Q, Kostic S, Wang X, Tong Z, Wang S, Wang J, Li W, Lee KS, Moon YW, Kang MJ, Hu X, Kim TY, Milenkovic D, Seo JH, Kim JH, Lee J, Kim SB. Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China; Liaoning Cancer Hospital, China; Harbin Medical University Cancer Hospital, China; Zhejiang Cancer Hospital, China; Tianjin Cancer Hospital, China; Sun Yat-sen University Cancer Center, Sun Yat-sen University, China; Linyi Cancer Hospital, China; First Affiliated Hospital of Jilin University, China; Fudan University Shanghai Cancer Center, and Shanghai Medical College, Fudan University, China; Asan Medical Center, University of Ulsan College of Medicine, Korea; Severance Hospital, Yonsei University College of Medicine, Korea; National Cancer Center, Korea; CHA Bundang Medical Center, CHA University College of Medicine, Korea; Inje University Haeundae Paik Hospital, Inje University College of Medicine, Korea; Seoul National University Hospital, Seoul National University College of Medicine, Korea; Korea University Guro Hospital, Korea; Gangnam Severance Hospital, Yonsei University College of Medicine, Korea; Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea College of Medicine, Korea; University of Belgrade, Faculty of Medicine, Clinical Hospital Center Bezanijska Kosa, Serbia; Clinical Center Nis, Faculty of Medicine, Serbia. HIGHLIGHTS In this Phase 3 trial, DHP107 (oral paclitaxel) was compared with weekly IV paclitaxel in HER2(-) metastatic breast cancer. DHP107 showed non-inferior PFS compared with paclitaxel (median 10.0 vs. 8.5 months; HR 0.869, 95% CI, 0.707-1.068). OS (median 32.6 months vs. 31.8 months) and tumor response rates (43.3% vs. 38. 8%) were also comparable. DHP107 had more neutropenia and GI toxicity and less hypersensitivity and neuropathy, with no treatment-related deaths. DHP107 may be a convenient, non-inferior, and safe alternative to IV paclitaxel in HER2-negative breast cancer. BACKGROUND: Intravenous (IV) paclitaxel requires prolonged infusion and is associated with hypersensitivity reactions and peripheral neuropathy. This study evaluated the efficacy and safety of DHP107, a novel oral formulation of paclitaxel, compared to IV paclitaxel in patients with HER2-negative, recurrent, or metastatic breast cancer. PATIENTS AND METHODS: This multinational, multicenter, open-label, randomized phase III trial evaluated the non-inferiority of DHP107 compared to IV paclitaxel, with a predefined non-inferiority margin of 1.33. Eligible patients had recurrent or metastatic breast cancer and had received no prior chemotherapy in the metastatic setting. Patients were randomized to receive either DHP107 (200 mg/m2 orally twice daily on days 1, 8, and 15) or paclitaxel (80 mg/m2 intravenously on days 1, 8, and 15) in a 28-day cycle. The primary endpoint was investigator-assessed progression-free survival (PFS) in the per-protocol set (PPS). Secondary endpoints included independent central review-assessed PFS, overall survival (OS), tumor response, quality of life (QoL), and safety. RESULTS: Between January 2018 and December 2023, 549 patients were randomized to receive either DHP107 (n=277) or paclitaxel (n=272); 519 patients were included in the PPS. DHP107 demonstrated non-inferiority in PFS with a median PFS of 10.0 months compared to 8.5 months for paclitaxel (hazard ratio [HR], 0.869; 95% confidence interval [CI], 0.707-1.068). The median OS was 32.6 months for DHP107 and 31.8 months for paclitaxel (HR 0.967; 95% CI, 0.762-1.227). DHP107 was associated with higher rates of neutropenia, febrile neutropenia, nausea, diarrhea, and vomiting, whereas peripheral neuropathy and hypersensitivity reactions were more common with paclitaxel. No treatment related-death occurred in the DHP107 group, and in one patient (0.4%) in the paclitaxel group. Quality of life was comparable between the two groups. CONCLUSIONS: DHP107 demonstrated non-inferior efficacy compared to IV paclitaxel, with a manageable safety profile, supporting its use as an effective and convenient alternative in HER2-negative breast cancer. KEYWORDS: DHP107, oral paclitaxel, non-inferiority, phase III, metastatic breast cancer DOI: 10.1016/j.annonc.2026.03.002 （来源：SIBCS）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

16 小时之前

·ioncology

晚期胃癌三线治疗疗效和安全性比较：系统综述与网络荟萃分析

点击蓝字，关注我们编者按：本文总结了发表于《肿瘤前沿》（Frontiers in Oncology）2023年3月的一篇系统综述与网络荟萃分析，通过网络荟萃分析方法，对比了免疫治疗、化疗、靶向治疗及抗体药物偶联物（ADC）等7种晚期胃癌（GC）及胃食管结合部癌（GEJC）三线治疗方案的疗效与安全性，为临床个体化治疗方案的制定提供了高级别证据支持。 01 前言胃癌（GC）和胃食管结合部癌（GEJC）已成为全球高发恶性肿瘤之一，在肿瘤相关死亡中位列第四。在中国，其发病率为29.3/10万，死亡率达21.2/10万。尽管手术及全身治疗取得一定进展，但胃癌整体5年生存率仍低于30%，晚期胃癌中位总生存期（OS）仅9–10个月，亟需更有效的多学科诊疗方案。目前，美国国家综合癌症网络（NCCN）指南推荐的一线标准治疗以氟尿嘧啶类为基础，联合铂类和/或紫杉类化疗，根据人表皮生长因子受体2（HER2）表达状态决定是否联合抗HER2药物，部分患者可依据程序性死亡配体1（PD-L1）表达添加免疫治疗。二线治疗以单药治疗为主，三线治疗则包含多种选择，如靶向治疗（阿帕替尼）、免疫治疗（纳武利尤单抗）、化疗（伊立替康、三氟尿苷替匹嘧啶）等。这些方案虽能带来生存获益，但肿瘤客观缓解率（ORR）仍较低（2.84%–11.6%）。近年来，新型ADC药物展现出显著疗效与可控安全性。德曲妥珠单抗（DS-8201）对HER2阳性胃癌患者疗效确切，整体安全性可控；RC48对HER2低表达和过表达患者均有高效抗肿瘤活性。晚期胃癌预后较差，传统化疗疗效有限，靶向药物选择匮乏，单药免疫治疗效果不足。本研究通过系统评价与网络荟萃分析，对比多种三线治疗方案的疗效与安全性，为临床选择最佳三线治疗方案提供参考。 02 研究方法本研究遵循PRISMA扩展声明开展，检索PubMed、Embase、Cochrane图书馆等数据库2005年1月至2021年11月发表的Ⅱ/Ⅲ期随机对照试验（RCT），并纳入2018-2022年主要肿瘤会议摘要。纳入标准为：比较至少两种三线治疗方案的英文RCT，患者经组织学确诊为Ⅳ期GC/GEJC，且提供OS、PFS相关风险比（HR）及95%置信区间（CI）。排除Ⅰ期试验、数据不全、非三线治疗及肿瘤疫苗相关研究。由两名研究者独立提取研究数据【基线特征、OS、PFS、疾病控制率（DCR）、3级及以上不良事件（AE）等】并采用Cochrane偏倚风险评估工具（针对RCT）和纽卡斯尔-渥太华量表（针对非RCT）进行质量评价。采用Q检验和I²统计量评估异质性，通过R软件JAGS和GEMTC包进行贝叶斯网络荟萃分析，计算累积排序曲线下面积（SUCRA）评估各治疗方案的排名概率。 03 结果经筛选最终纳入5项Ⅱ/Ⅲ期RCT，共1674例患者，涉及7种治疗方案，包括免疫治疗（纳武利尤单抗）、化疗（三氟尿苷替匹嘧啶、伊立替康、紫杉醇）、靶向治疗（阿帕替尼）及ADC（德曲妥珠单抗、RC48），所有研究满足传递性假设（图1）。对不同RCT中同一治疗方案的mOS进行整合分析显示，阿帕替尼作为GC/GEJC三线治疗的汇总OS（pOS）为5.59个月（95% CI，3.96–7.21），ADC类药物的pOS为10.12个月（95% CI，5.61–14.62）。图1. 胃/胃食管结合部腺癌（GC/GEJC）三线治疗方案的网络荟萃分析中各治疗总生存期（OS）比较的网络关系图。每个圆形节点代表一种治疗方案。节点的大小和连线的粗细分别根据评估各治疗方案的文献数量和直接比较的研究数量进行加权。括号内显示了接受各治疗方案的患者总数。在主要疗效指标方面， OS对比显示，与安慰剂相比，纳武利尤单抗（HR=0.66，95% CI，0.54–0.80）、阿帕替尼（HR=0.61，95% CI，0.48–0.78）、德曲妥珠单抗（HR=0.41，95% CI，0.26–0.64）及化疗（HR=0.69，95% CI：0.56–0.85）均能显著延长患者OS，且德曲妥珠单抗较化疗的OS获益更显著（HR=0.59，95% CI，0.39–0.89）。 SUCRA值显示德曲妥珠单抗（0.98）排名第一，其次为阿帕替尼（0.63）和纳武利尤单抗（0.49）（图2A）。PFS方面，上述四种治疗方案的PFS均显著优于安慰剂，其中德曲妥珠单抗的SUCRA值最高（0.97），阿帕替尼（0.77）次之（图2A）。DCR对比中，阿帕替尼（RR=4.90，95% CI，2.96–8.89）、德曲妥珠单抗（RR=4.30，95% CI，2.75–7.14）、化疗（RR=3.09，95% CI，2.09–4.85）及纳武利尤单抗（RR=1.61，95% CI，1.18–2.28）均优于安慰剂，阿帕替尼（SUCRA=0.89）和德曲妥珠单抗（0.84）排名前列（图2B）。图2：晚期胃/胃食管结合部腺癌（GC/GEJC）三线治疗方案的网络荟萃分析结果。（A）总人群中总生存期（OS）与无进展生存期（PFS）的合并风险比（HR）[95%可信区间（CI）]。（B）总人群中疾病控制率（DCR）与3级及以上不良事件（≥3级AE）的合并相对危险度（RR）（95% CI）。（C）HER2阳性以及HER2免疫组化2+/荧光原位杂交阴性或免疫组化1+患者总生存期（OS）的合并HR（95% CI）。亚组分析结果显示，HER2阳性患者中，德曲妥珠单抗（HR=0.45；95% CI：0.23–0.89）和纳武利尤单抗（HR=0.38；95%CI：0.22–0.66）的OS显著优于安慰剂，且德曲妥珠单抗较化疗更具优势（HR=0.59；95%CI：0.39–0.88）（图2C）；在HER2低表达或阴性患者中，纳武利尤单抗的SUCRA值（0.61）高于化疗（0.39）。病理类型亚组中，肠型和弥漫型胃癌患者的德曲妥珠单抗SUCRA值均最高，分别为0.95和0.98。其他亚组中，有胃切除术史、胃癌原发、年龄＞65岁、体力状态评分（ECOG PS）=0/1的患者中，ADC类药物排名第一；而GEJC患者中，纳武利尤单抗的SUCRA值（0.83）最高，为最佳选择。安全性方面，纳武利尤单抗（RR=2.82；95% CI，1.36–6.86）和化疗（RR=4.07；95% CI，2.78–6.31）的≥3级AEs发生率高于安慰剂。阿帕替尼最常见的不良事件为高血压（5.4%）和手足综合征（7.6%），血液毒性和胃肠道相关不良事件发生率较低；德曲妥珠单抗则以白细胞减少（21%）和贫血（38%）为主，整体安全性可控。 04 讨论本研究证实，纳武利尤单抗、阿帕替尼、化疗及ADC类药物均能显著改善GC/GEJC患者OS。ADC类药物（以德曲妥珠单抗为代表）在总体人群中表现最佳，其SUCRA值在OS（0.98）和PFS（0.97）中均居首位，且在HER2过表达、肠型病理、有胃切除术史、胃癌原发、年龄＞65岁及ECOG PS=0/1等亚组中均为最优选择，这与德曲妥珠单抗的作用机制相关——通过HER2受体内化进入肿瘤细胞，经溶酶体酶 cleavage释放拓扑异构酶I抑制剂DXd，精准攻击肿瘤细胞，对HER2过表达或异质性表达肿瘤尤为有效。而德曲妥珠单抗在 HER2 阳性人群中的卓越疗效，也在针对中国患者的 DESTINY-Gastric06 研究中得到了进一步验证与夯实，该研究作为贴合中国临床诊疗现状的桥接研究，为德曲妥珠单抗在本土 HER2 阳性晚期胃癌患者中的三线应用提供了极具价值的循证依据。 DESTINY-Gastric06 是一项开放标签、单臂、多中心的 Ⅱ 期临床研究，专门纳入既往接受过至少两种治疗方案（含氟尿嘧啶和铂类药物）的中国 HER2 阳性局部晚期 / 转移性胃癌或胃食管结合部腺癌患者，研究入组患者不仅基线特征更差，更高比例为 ECOG PS 1 分、胃食管结合部癌及肿瘤负荷较大人群，且近九成患者既往接受过曲妥珠单抗治疗，超三成接受过新型抗 HER2 治疗，同时研究开展于新冠疫情高峰期，存在治疗延迟、随访不规律等非理想治疗条件，更能真实反映临床实际用药情况。即便在这样的研究背景下，德曲妥珠单抗仍展现出稳定且优异的抗肿瘤活性，在 73 例经中心实验室确认的 HER2 阳性患者全分析集中，经独立中心审查（ICR）和研究者评估（INV）的mPFS均达到 5.7 个月，mOS为 11.1 个月，若剔除 4 例因新冠疫情死亡的病例进行敏感性分析，mOS 可提升至 12.4 个月，成功实现总生存期突破 1 年的生存获益，与国际上的 DESTINY-Gastric01 研究疗效高度一致。在肿瘤缓解与控制方面，该研究中德曲妥珠单抗经 ICR 确认的ORR达 28.8%，其中 1 例患者实现完全缓解，研究者评估的 ORR 为 37.0%，ICR 和 INV 评估的DCR也分别达到 79.5% 和 78.1%，即便受疫情影响缓解数据略有波动，仍优于现有其他治疗药物，充分证实了其在经多线治疗的中国 HER2 阳性胃癌患者后线治疗中，具备强效的缩瘤能力与持久的疾病控制效果。本研究中，德曲妥珠单抗在HER2阳性患者中SUCRA值（0.85）高于纳武利尤单抗（0.80）和化疗（0.29），且在HER2低表达患者中仍展现临床活性，拓展了治疗获益人群。而 DESTINY-Gastric06 研究的结果，则进一步印证了德曲妥珠单抗在 HER2 阳性人群中的疗效普适性，即便面对经曲妥珠单抗及新型抗 HER2 治疗失败的中国患者，该药物依旧能将抗肿瘤活性转化为明确的生存获益，也让本研究中德曲妥珠单抗针对 HER2 阳性亚组的疗效结论，得到了更贴合中国本土患者特征的临床数据支撑，为该药物在国内 HER2 阳性晚期胃癌三线治疗中的应用提供了更坚实的实践依据。 GEJC患者中纳武利尤单抗表现最优，可能与西方人群GEJC发病率较高、部分病理类型（如鳞癌）对免疫治疗应答更佳相关。值得注意的是，所有三线治疗方案对女性患者OS无显著改善，可能与女性患者样本量较小、病理类型以低分化腺癌和印戒细胞癌为主（对治疗应答较差）有关。综上，ADC类药物是晚期胃癌总体人群的最佳三线治疗选择，尤其适用于HER2过表达、肠型病理等亚组患者；纳武利尤单抗则为GEJC患者的首选方案，而 DESTINY-Gastric06 研究的结果也让德曲妥珠单抗在 HER2 阳性中国晚期胃癌患者中的三线治疗价值得到进一步明确，临床需结合患者的分子分型、疾病特征、基线状态等具体情况制定精准化的治疗策略。 ▌参考文献： [1] Zhang C, et al. Comparison of the efficacy and safety of third-line treatments for advanced gastric cancer: A systematic review and network meta-analysis. Front Oncol. 2023;13:1118820. [2] Peng Z, et al. Trastuzumab deruxtecan in patients from China with previously treated human epidermal growth factor receptor 2-positive locally advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (DESTINY-Gastric06): results from a single-arm, multicenter, phase 2 trial. eClinicalMedicine, 2025, 87, 103404. 本资料仅供医疗卫生专业人士参考，请勿向非医疗卫生专业人士发放CN-20260316-00003，有效期2028年3月15日（来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

22 小时之前

·美迪西Medicilon

美迪西助力合作伙伴济煜医药KRAS G12C抑制剂获批上市

2月28日，上海济煜医药自主研发的1类抗肿瘤创新药硫酸索西美雷塞片（JMKX001899，商品名：济乐美®）已获国家药品监督管理局批准上市，用于治疗至少接受过一种系统性治疗的鼠类肉瘤病毒癌基因KRAS G12C突变型的晚期非小细胞肺癌(NSCLC)成人患者。美迪西助力上海美迪西生物医药股份有限公司作为济煜医药的长期合作伙伴，遵循中美双报的GLP标准，为硫酸索西美雷塞片提供了安全性评价研究服务，加速了药物研发进程。硫酸索西美雷塞片：KRAS G12C抑制剂新星，差异化优势显著硫酸索西美雷塞片是济煜医药研发的一款新型、口服、强效的KRAS G12C共价抑制剂，获批基于一项关键II期临床研究，研究结果显示，该药在疗效和安全性方面均表现出色：强效控瘤：经独立评审委员会（IRC）评估，患者的客观缓解率（ORR）为52.4%，疾病控制率（DCR）达87.6%，中位无进展生存期（PFS）为7.2个月。中位DOR和OS尚未达到，显示出了持久的疗效潜力。安全性优：数据显示，95.2%（138例）患者报告治疗相关不良事件（TRAE），3-4级TRAE发生率为40.0%（58例），无致死性TRAE。临床前研究显示，与同类产品相比，济乐美具有较强的脑通透性，且未观察到心脏毒性及明显药物相互作用风险，这为其在肺癌脑转移患者中建立差异化优势提供了可能。给药便捷：口服给药，每日一次，一次两片，给药频次少、剂量低，减轻患者服用负担。广谱潜力：目前除了 NSCLC（国内获批上市，美国 I 期），硫酸索西美雷塞还拓展了不同的适应症，包括结直肠癌（美国 I 期）、胰腺癌（美国 I 期）。硫酸索西美雷塞片是济煜医药首个完全基于自身研发平台，从早期发现、临床研究到最终获批上市的原创药物。在商业化布局上，该药在大中华区以外的开发、生产及商业化权利独家许可给沪亚。此次获批上市，不仅是济煜医药研发体系成熟度与创新转化能力的集中体现，更彰显了本土创新药企在肿瘤靶向治疗领域的硬核实力。美迪西：一站式临床前研发服务，助力KRAS靶向新药开发 KRAS是人类癌症中最常见的突变致癌基因之一，其中G12C突变是关键的药物研发靶点。美迪西在KRAS靶点药物研发领域积累了丰富的经验，可提供涵盖药物发现、CMC研究（原料药和制剂）、药效学研究、药代动力学研究以及安全性评价在内的临床前研发一站式服务，已成功助力多款KRAS靶向新药获批临床。此次硫酸索西美雷塞片获批上市，是美迪西与济煜医药深度合作的又一重要成果。美迪西将持续夯实一站式生物医药临床前研发平台，致力于以高效、可靠的研发服务，赋能全球创新伙伴，加速每一个突破性疗法从愿景走向现实。关于济煜医药上海济煜医药科技股份有限公司2018年创立于上海浦东，专注于创新药物的研发、制造和商业转化。凭借卓越的药物开发能力和研产销一体化整合，济煜医药致力于快速推动自主创新药物进入全球市场，以解决患者未被满足的医疗需求。目前有40＋在研项目，19+项目在国内外进入临床阶段，研究范围包含了肿瘤、自免、肾病和疼痛领域。未来济煜医药将持续推进创新药物开发，不断打造新质生产力，致力于成为国际先进的现代化创新型医药企业，为提高人类健康水平而不懈努力！相关推荐全球首个B7-H3/PSMA双抗ADC！美迪西祝贺多禧生物DXC014完成首例患者给药 ➠ 美迪西助力翰思艾泰全球首创OX40靶向ADC药物HX111获批临床 ➠ 美迪西助力新通药物MASH新药1类创新药XTYW007片获批临床➠ 助力创新药物出海+1！美迪西祝贺宜联生物B7H3 ADC授权罗氏 ➠ 美迪西祝贺德睿智药口服小分子减重药MDR-001启动III期临床 ➠ 美迪西祝贺海博为药业HBW-3220胶囊进入关键性Ⅲ期临床研究 ➠ 美迪西助力信诺维口服蛋白降解剂XNW34017获批临床 ➠ 美迪西助力安炎达医药MAX-001胶囊获批临床 ➠ 美迪西助力美济医药全球首个口服紫杉醇软胶囊中美双报双批 ➠ 美迪西助力泰恩康CKBA乳膏再获临床试验批准 ➠ 直播预告关于美迪西美迪西（SHA: 688202）成立于2004年，专注于为全球制药企业、研究机构及科研工作者提供全方位的临床前新药研发服务。公司构建了覆盖药物发现、药学研究至临床前研究的一站式综合研发平台，并在ADC、核酸、多肽、CGT、Protac、抗体等前沿领域搭建了服务平台。公司建立了符合国际规范的质量体系，已获得中国NMPA、美国FDA、欧盟OECD等GLP认证以及AAALAC国际认证。目前，公司在国内外拥有近8万平方米研发实验室。至2025年末，公司已为全球超2000家客户提供药物研发服务，参与研发完成的新药及仿制药项目有610+件IND获批临床，携手国内外合作伙伴共同推动药物创新突破。美迪西将继续立足全球，聚力创新，为人类健康贡献力量！欢迎访问公司官网 www.medicilon.com了解更多详情。

100 项与紫杉醇相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00491	紫杉醇	L01CD01	DB01229

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
晚期胃癌	中国	DAE HWA PHARM Co., Ltd.	2024-09-19
晚期胃癌	中国	上海海和药物研究开发股份有限公司	2024-09-19
转移性胰腺腺癌	欧盟	Accord Healthcare SLU	2024-01-05
转移性胰腺腺癌	冰岛	Accord Healthcare SLU	2024-01-05
转移性胰腺腺癌	列支敦士登	Accord Healthcare SLU	2024-01-05
转移性胰腺腺癌	挪威	Accord Healthcare SLU	2024-01-05
铂类耐药性原发性腹膜癌	欧盟	Inceptua SA	2018-11-20
铂类耐药性原发性腹膜癌	冰岛	Inceptua SA	2018-11-20
铂类耐药性原发性腹膜癌	列支敦士登	Inceptua SA	2018-11-20
铂类耐药性原发性腹膜癌	挪威	Inceptua SA	2018-11-20
铂敏感性卵巢上皮癌	欧盟	Inceptua SA	2018-11-20
铂敏感性卵巢上皮癌	冰岛	Inceptua SA	2018-11-20
铂敏感性卵巢上皮癌	列支敦士登	Inceptua SA	2018-11-20
铂敏感性卵巢上皮癌	挪威	Inceptua SA	2018-11-20
铂敏感性输卵管癌	欧盟	Inceptua SA	2018-11-20
铂敏感性输卵管癌	冰岛	Inceptua SA	2018-11-20
铂敏感性输卵管癌	列支敦士登	Inceptua SA	2018-11-20
铂敏感性输卵管癌	挪威	Inceptua SA	2018-11-20
生殖细胞瘤	日本	Bristol Myers Squibb Co.	2013-02-21
生殖细胞瘤	日本	Clinigen KK	2013-02-21

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
胰腺癌	申请上市	欧盟	Accord Healthcare SLU	2023-11-09
转移性胰腺癌	临床3期	中国	上海谊众药业股份有限公司	2025-01-21
高级别胶质瘤	临床3期	中国	浙江大学	2024-04-01
HEGF2阴性乳腺癌	临床3期	中国	上海谊众药业股份有限公司	2023-09-25
皮肤鳞状细胞癌	临床3期	美国	ECOG-ACRIN Medical Research Foundation, Inc.	2023-06-08
下咽癌	临床3期	美国	ECOG-ACRIN Medical Research Foundation, Inc.	2023-06-08
转移性头颈部鳞状细胞癌	临床3期	美国	ECOG-ACRIN Medical Research Foundation, Inc.	2023-06-08
下咽部鳞状细胞癌	临床3期	美国	ECOG-ACRIN Medical Research Foundation, Inc.	2023-06-08
喉鳞状细胞癌	临床3期	美国	ECOG-ACRIN Medical Research Foundation, Inc.	2023-06-08
口腔鳞状细胞癌	临床3期	美国	ECOG-ACRIN Medical Research Foundation, Inc.	2023-06-08

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03179904 (CTgov)	临床2期	HER2阳性乳腺癌 \| HER2阳性转移性乳腺癌 \| 晚期乳腺癌	17	trastuzumab+FASN inhibitor TVB-2640+paclitaxel (Cohort A)	糧齋顧鑰餘鹽獵窪夢選 = 蓋鏇糧構鏇構餘遞築願壓淵顧築糧選選積淵構 (衊鏇壓醖觸襯鏇壓鏇願, 膚鬱鬱窪艱鏇糧網顧範 ~ 襯遞糧觸壓繭構衊簾製) 更多	-	2026-02-24
				trastuzumab+FASN inhibitor TVB-2640+fulvestrant+letrozole+paclitaxel+exemestane+anastrozole (Cohort B)	糧齋顧鑰餘鹽獵窪夢選 = 糧繭範淵壓範壓選構願壓淵顧築糧選選積淵構 (衊鏇壓醖觸襯鏇壓鏇願, 齋餘簾築壓蓋蓋網鹹顧 ~ 繭餘艱顧醖淵糧製鑰積) 更多
NCT03101748 (CTgov)	临床1/2期	炎症性乳腺肿瘤 \| 乳腺癌 \| 局部晚期乳腺癌 ... 更多	34	trastuzumab+neratinib+paclitaxel+pertuzumab (Cohort 1 Phase Ib Dose Level 0)	獵構獵夢膚鏇憲餘夢鑰 = 鹹簾夢壓觸醖鑰鬱壓遞艱壓鹹獵壓鏇遞製衊夢 (簾襯範選壓願夢鑰願憲, 壓鹽餘壓簾選糧膚膚築 ~ 範鹽構簾壓製蓋廠醖餘) 更多	-	2026-02-12
				trastuzumab+neratinib+paclitaxel+pertuzumab (Cohort 1 Phase Ib Dose Level 1)	獵構獵夢膚鏇憲餘夢鑰 = 構衊襯範獵簾蓋廠襯構艱壓鹹獵壓鏇遞製衊夢 (簾襯範選壓願夢鑰願憲, 顧範艱艱廠願壓觸獵齋 ~ 襯醖鬱糧選製網蓋簾夢) 更多
NCT03829722 (CTgov)	临床2期	口咽部鳞状细胞癌 \| 人乳头瘤病毒相关的头颈部肿瘤	26	Radiation Therapy+Nivolumab+Carboplatin+Paclitaxel	繭醖夢遞蓋壓鏇鬱獵選 = 糧築選醖餘蓋觸餘鹽壓鬱餘壓窪淵簾壓觸糧範 (鹽鬱醖構鏇遞艱襯淵構, 鏇構鹹襯餘遞餘蓋夢壓 ~ 鑰窪艱衊蓋構糧糧衊鏇) 更多	-	2026-01-22
NCT04770272 (neoMono, CTgov)	临床2期	三阴性乳腺癌	442	Biopsy Arm A+Cyclophosphamide+Carboplatin+Paclitaxel+Atezolizumab 840 MG in 14 ML Injection+epirubicin (Arm A)	觸蓋窪夢膚壓襯選築構 = 鬱鏇襯願壓艱遞蓋壓糧夢壓範網醖淵遞壓獵夢 (鹽壓構膚構遞積膚遞顧, 膚鬱繭蓋網觸蓋襯積鬱 ~ 範廠繭遞壓淵窪糧繭範) 更多	-	2026-01-12
				Biopsy Arm B+Cyclophosphamide+Carboplatin+Paclitaxel+Atezolizumab 1200 MG in 20 ML Injection+epirubicin (Arm B)	觸蓋窪夢膚壓襯選築構 = 觸顧選糧壓窪鏇鹹壓鏇夢壓範網醖淵遞壓獵夢 (鹽壓構膚構遞積膚遞顧, 襯網構齋願夢鬱製顧夢 ~ 獵鏇鑰廠窪鏇憲簾壓構) 更多
NCT02931890 (CRITICS-II, ASCO_GI2026 \| NEWS) 人工标引	临床2期	胃癌新辅助	201	docetaxel+oxaliplatin+capecitabine	鹹淵顧糧憲範衊憲遞鹹(獵鏇壓鏇鹽積鑰築範窪) = 壓築淵餘構鑰鏇廠鏇遞網範製獵範襯獵廠觸製 (鹹獵廠淵壓蓋憲願衊製, 58 ~ 80) 更多	积极	2026-01-08
				docetaxel+oxaliplatin+capecitabine+45Gy/25 fractions + paclitaxel or carboplatin	鹹淵顧糧憲範衊憲遞鹹(獵鏇壓鏇鹽積鑰築範窪) = 窪築遞齋範鹹鏇艱鹽網網範製獵範襯獵廠觸製 (鹹獵廠淵壓蓋憲願衊製, 75 ~ 94) 更多
NCT04660760 (ACCRU-GI-1810, ASCO_GI2026)	临床2期	晚期胃食管交界处腺癌二线	29	FTD-TPI+RAM	繭壓築願簾淵蓋簾壓蓋(艱餘獵淵淵獵鑰膚鏇鹽) = 衊淵齋網願範構遞齋衊醖襯糧顧襯鹹觸積廠衊 (構築構選淵淵廠膚遞膚 ) 更多	不佳	2026-01-08
				PAC+RAM	繭壓築願簾淵蓋簾壓蓋(艱餘獵淵淵獵鑰膚鏇鹽) = 廠遞糧鹽鏇網衊窪願艱醖襯糧顧襯鹹觸積廠衊 (構築構選淵淵廠膚遞膚 ) 更多
NCT04762953 (STOPGAP, ASCO_GI2026)	临床2期	腹膜癌巩固	31	IP PTX + systemic therapy	積廠糧壓選製範壓襯衊(醖壓遞襯範壓壓餘鏇鹹) = 淵顧蓋鏇網獵願繭醖壓鬱觸鬱齋網選膚鏇鹹選 (蓋遞淵鬱製鹹壓窪築窪 ) 更多	积极	2026-01-08
NCT03199885 (NRG-BR004, CTgov)	临床3期	复发性乳腺癌 \| HER2阳性转移性乳腺癌 \| 不能切除的乳腺癌	190	Computed Tomography+Trastuzumab+Paclitaxel+Pertuzumab+Docetaxel (Arm I (Pertuzumab, Trastuzumab, Taxane Therapy, Placebo))	繭積網廠壓築窪廠繭製 = 構糧積鏇觸齋繭範製窪糧鹹夢遞製膚襯窪鏇膚 (膚願夢觸獵齋網餘齋製, 鏇築醖願蓋窪廠遞衊壓 ~ 糧網鹽顧淵積構鹽簾夢) 更多	-	2025-12-30
				Computed Tomography+Trastuzumab+Paclitaxel+Pertuzumab+Docetaxel+Atezolizumab (Arm II (Pertuzumab, Trastuzumab, Taxane Therapy, Atezolizumab))	繭積網廠壓築窪廠繭製 = 蓋壓醖蓋齋齋製顧鹹鬱糧鹹夢遞製膚襯窪鏇膚 (膚願夢觸獵齋網餘齋製, 遞窪襯範網衊簾襯齋醖 ~ 鏇淵網夢齋鏇淵範蓋廠) 更多
NCT05276973 (CTgov)	临床1期	原发性腹膜癌 \| 原发性腹膜高级别浆液性腺癌 \| 原发性腹膜子宫内膜样腺癌 ... 更多	25	carboplatin+Paclitaxel+ipatasertib (DL1 Dose Escalation Cohort)	獵願醖醖襯襯廠夢夢顧 = 餘醖網淵壓廠壓艱積鑰鬱構憲鏇齋範窪蓋選夢 (築遞願膚窪觸餘醖鑰獵, 選築廠醖範餘窪鬱襯遞 ~ 憲獵衊窪範憲顧顧鹹網) 更多	-	2025-12-19
				carboplatin+Paclitaxel+ipatasertib (DL2 Dose Escalation Cohort)	獵願醖醖襯襯廠夢夢顧 = 網蓋積鑰繭壓製遞築餘鬱構憲鏇齋範窪蓋選夢 (築遞願膚窪觸餘醖鑰獵, 鏇顧蓋願鬱網淵選範積 ~ 顧餘衊範網鑰遞築膚簾) 更多
NCT03132532 (CTgov)	临床2期	复发性非小细胞肺癌 \| 不可切除的非小细胞肺癌	20	Quality-of-Life Assessment+Etoposide+Carboplatin+Pemetrexed+Paclitaxel+cisplatin (Arm A (Platinum Doublet Chemotherapy, Lower Dose PBT))	鑰餘衊鬱積艱簾醖淵廠 = 積糧積憲淵蓋窪艱鹹獵鏇壓憲願獵齋衊鬱糧壓 (構蓋網選齋簾願艱襯願, 獵衊憲構簾蓋壓淵膚鏇 ~ 觸觸憲鬱積繭鑰鹹選獵) 更多	-	2025-11-25
				Quality-of-Life Assessment+Carboplatin+Paclitaxel (Arm C (Platinum Doublet Chemotherapy, Higher Dose PBT))	鑰餘衊鬱積艱簾醖淵廠 = 夢膚艱鹽觸鬱鏇淵獵顧鏇壓憲願獵齋衊鬱糧壓 (構蓋網選齋簾願艱襯願, 築艱鏇鹽鹽顧製鬱齋壓 ~ 衊鬱繭願積簾網選齋繭) 更多